← Back to headlines
Outlook Therapeutics Appoints Kevin Lundquist as CFO Ahead of U.S. Commercial Launch of LYTENAVA™
Outlook Therapeutics has named Kevin Lundquist as its new Chief Financial Officer as the company prepares for the commercial rollout of its drug LYTENAVA™ in the United States.
27 Aug, 20:05 — 27 Aug, 20:05
